Biotop-report 2013

Innovation for better health.  Our  commitment  

is  to  bring  to  patients  around  the  world  quality  

medicines  for  use  in  diag nosing,  combating  and 

preventing disease. Every day we work against time, 

researching  new  pathways,  new  molecules,  new 

technologies – complementing our own capabilities 

with  exper tise  of  innovative  partners  from  science 

and industry. 

The  success  of  this  work  is  evidenced  in  new  

med­i­cines­for­areas­with­significant­unmet­medical­

need  such  as  oncology,  cardiovascular  and  blood 

diseases, as well as gynecology and ophthalmology. 

Our aim is a better quality of life for all.

You need commitment, focus and  

passion to find new ways to fight the  

diseases of this world: innovation  

is at the heart of it.

www.bayerhealthcare.com

www.bayerpharma.com

29409006_BHC_Imageanzeige_210x297_mm_Lay_20130515_TR.indd   1

15.05.13   14:03

---

18

BioTOPics 46 | September 2013 

BioTOP-Report

Diagnostics

An Excellent Location for the Development of 

Innovative Diagnostics

In Berlin-Brandenburg bioanalysis is a focus area of research and development. Some 100 companies and 

more than 20 research facilities present the entire value chain from biomarker identification through clinical 

validation to the production of in vitro-diagnostics. 

Early, specific and reliable laboratory diagnostics makes a key 

contribution to disease detection, therapy optimisation, and pre-

vention. Its importance can therefore barely be overrated, given 

the many challenges facing our healthcare systems. Progress in 

biomedical basic research and the development of new analytical 

techniques and methods has resulted in a tremendous increase 

in the performance of diagnostic laboratories over the past de-

cades.

New sensor-actor molecules, autonomous biosensors, genome, 

proteome and glycan-based multiplex analytics as well as metab-

olomics platforms provide the foundation for the development 

and implementation of innovative biomarker strategies. Com-

panion diagnostics for personalised medicine are rapidly gaining 

in importance based on these new insights and developments.

In light of this, Berlin-Brandenburg has become an internation-

ally leading location for research and development in laboratory 

medicine and for the implementation of clinical studies. The wide 

range of specialised hospitals, clinics for both basic and advanced 

care as well as the high-performance university medicine at the 

Charité provide access to patient cohorts of the urban and ru-

ral population with some 180 different ethnic backgrounds and 

covering virtually all medical themes. The development of the 

German capital region as an internationally desired location for 

diagnostics development is an outstanding example for the suc-

cessful implementation of the Common Innovation Strategy of 

the States of Berlin and Brandenburg (innoBB) and a major com-

ponent of the HealthCapital cluster.

Diagnostic know-how for outstanding development 

and patient care 

Labor Berlin – Charité Vivantes GmbH is Europe‘s largest clini-

cal laboratory, providing optimal conditions for driving the de-

velopment of innovative diagnostics in cooperation with leading 

companies like BioMérieux, Roche Diagnostics and Thermo Fish-

er Scientific. Labor Berlin is participating in the development of 

a fully integrated automation solution in microbiology and has 

introduced a platform for next-generation sequencing (NGS) into 

routine analysis. 

Since April 2013, the clinical laboratory has been standardising 

its operations in a single location at the Charité Campus Vir-

Dr. Florian Kainzinger

Managing Director  

Labor Berlin – Charité Vivantes GmbH

With our new central location, we have established the foun-

dation for intensive interdisciplinary exchange between the 

specialist laboratories and for the integration of clinical exper-

tise. This high expertise, methodological competence and our 

high routine sample volumes of more than 35 million analyses 

per annum for more than 400,000 hospital and some one 

million outpatients contribute to optimal patient care, while 

also forming an ideal basis for the development of improved 

IVD technologies.

Ene

rgy

Aut

omation

Phot

onics

Indus

trial Sof

tware

Sof

twa

re

Inter

net & T

elecommunication

Media & E-commerce

Life Science

Mater

ial Science

Nanotechnology & Chemis

try

I N V E S T O R S   O F   H I G H - T E C H   G R U E N D E R F O N D S   I I

Achieve innovation, 

shape the future

High Tech Gruenderfonds is your partner for Seed Stage investing. We 

help out young, high potential startups in the early phases of technology 

and product development, as well as successful launching.  Our assistance 

is not limited to our cash investments, instead we strive to add long term 

added-value to portfolio companies through our extensive network of 

professional and our accredited coaches.

High-Tech Gründerfonds Management GmbH

Schlegelstraße  2 | 53113 Bonn 

Phone: [phone] |  Fax:  [phone]   

E-Mail:    [e-mail]

http: // www.high-tech-gruenderfonds.de

Start shot for young technology companies

---